Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection

• Status: Withdrawn
• Trial end date: 2020-11-20
• Target enrollment: 0
• Participant gender: All

Summary

The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations.

Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics.

The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Limoges
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

1. Major patient

2. Relating to palliative care

3. With sars-cov-2 infection

4. Requiring light to moderate sedation corresponding to a RASS score of -1 to -3

Exclusion Criteria:

1. Pregnant, lactating woman.

2. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the summary of product characteristics

3. Advanced heart block (level 2 or 3) unless a pacemaker.

4. Uncontrolled hypotension.

5. Acute cerebrovascular pathologies.

6. Use of other sedative drugs